Endocrine Abstracts

Objective: Randomized trials demonstrated a lower risk of cardiovascular (CV) events with sodium – glucose cotransporter-2 inhibitors (SGLT-2i) in patients with type 2 diabetes(T2D) at high CV risk. SGLT2-i should be considered as a valuable therapy in T2D with established atherosclerotic cardiovascular disease (ASCVD) or heart failure (HF). We analyzed the effects of cardiovascular function of SGLT 2 inhibitors in T2D with ASCVD or HF compared with dipeptidyl peptidase-4...

Objective: Dapagliflozin, sodium-glucose cotransporter-2 (SGLT-2) inhibitor, reduces hyperglycemia and body weight by inhibiting renal glucose reabsorption. However, only a few studies have shown the efficacy of dapagliflozin in type 2 diabetic patients. We evaluated the efficacy and safety of body weight reduction of dapagliflozin in real practice with type 2 diabetes in Korea.Methods: This is a retrospective, observational study, data from 61 patients ...

Objective: This study was performed to determine the impact on quality of life and sleep impairment of painful diabetic peripheral neuropathy (PDPN).Research design and method: The study pool consisted of 200 randomly selected peoples with type 2 diabetic peripheral neuropathy. PDPN was diagnosed using visual analogue scales (VAS) and medical history. The patients were asked to answer the Brief Pain Inventory-Short Form (BPI-SF), Medical Outcomes Study S...

Introduction: Occurrence of follicular thyroid carcinoma (FTC) is limited almost within thyroid gland, but distant metastasis is discovered uncommonly as first presentation. We experienced a rare case about recurrent bone metastasis of FTC with unknown primary site.Case report: A 58-year-old woman complained about back pain for 3 years. A 5 cm sized mass in right 8th posterior rib was discovered and performed resection. The result of pathology was bone m...

Objective: Dapagliflozin, sodium-glucose cotransporter-2 (SGLT-2) inhibitor, reduces hyperglycemia and body weight by inhibiting renal glucose reabsorption. However, only a few studies have shown the glycemic efficacy on a combination of dapagliflozin in type 2 diabetic patients in Korean. We evaluated the efficacy and safety of glucose control on a combination of dapagliflozin in people with type 2 diabetes in Korea.Methods: This is a retrospective, obs...